FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer
https://www.zacks.com/stock/news/2323310/fda-expands-astrazeneca-s-azn-imfinzi-label-in-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2323310
Aug 16, 2024 - This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.
0
Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal
https://www.zacks.com/stock/news/2323142/pharma-stock-roundup-azn-gets-approvals-for-imfinzi-expanded-use-mrk-inks-new-deal?cid=CS-ZC-FT-analyst_blog|stock_roundup-2323142
Aug 16, 2024 - Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.
0
Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2320139/ironwood-irwd-q2-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2320139
Aug 09, 2024 - Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.
0
Top Analyst Reports for AstraZeneca, TotalEnergies & ConocoPhillips
https://www.zacks.com/commentary/2318154/top-analyst-reports-for-astrazeneca-totalenergies-conocophillips?cid=CS-ZC-FT-research_daily-2318154
Aug 07, 2024 - Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), TotalEnergies SE (TTE) and ConocoPhillips (COP).
0
How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?
https://www.zacks.com/stock/news/2316191/how-should-you-play-astrazeneca-abbv-after-q2-beat-view-raise?cid=CS-ZC-FT-analyst_blog|rank_focused-2316191
Aug 05, 2024 - AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.
0
Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View
https://www.zacks.com/stock/news/2312245/merck-mrk-q2-earnings-sales-beat-estimates-cuts-24-eps-view?cid=CS-ZC-FT-analyst_blog|earnings_article-2312245
Jul 30, 2024 - Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.
0
3 Surprisingly Underrated Stocks to Buy Right Now
https://www.fool.com/investing/2024/07/26/3-surprisingly-underrated-stocks-to-buy-right-now/?source=iedfolrf0000001
Jul 26, 2024 - These stocks arguably deserve more respect from investors.
0
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
https://www.zacks.com/stock/news/2310103/pharma-stock-roundup-azn-sny-abbv-q2-earnings-pfe-mrk-s-positive-pipeline-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2310103
Jul 26, 2024 - AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
0
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
https://www.zacks.com/stock/news/2306156/ema-begins-review-of-bristol-myers-bmy-opdivo-plus-yervoy-for-hcc?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2306156
Jul 22, 2024 - Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
0
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
https://www.zacks.com/stock/news/2305396/ionis-ions-completes-enrolment-for-rare-disease-drug-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2305396
Jul 19, 2024 - Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
0